Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.

Wu, Tzong-YowTzong-YowWuPAO-YU CHENJANN-TAY WANGWANG-DA LIUYEE-CHUN CHENSHAN-CHWEN CHANG2024-07-032024-07-032024-05-02https://scholars.lib.ntu.edu.tw/handle/123456789/719599enSuboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.journal article10.1093/jac/dkae08238538154